title: Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis.
authors.affiliation: Klinik für Gastroenterologie und Rheumatologie, Universitätsklinikum Leipzig, Leipzig, Germany. johannes.wiegand@medizin.uni-leipzig.de.
authors.forename: J
authors.initials: J
authors.lastname: Wiegand
authors.forename: B
authors.initials: B
authors.lastname: Maasoumy
authors.forename: P
authors.initials: P
authors.lastname: Buggisch
authors.forename: A
authors.initials: A
authors.lastname: Buslau
authors.forename: I
authors.initials: I
authors.lastname: Schiefke
authors.forename: T
authors.initials: T
authors.lastname: Berg
authors.forename: H
authors.initials: H
authors.lastname: Wedemeyer
authors.forename: C
authors.initials: C
authors.lastname: Sarrazin
authors.forename: H
authors.initials: H
authors.lastname: Hinrichsen
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D005260:Female; D006526:Hepatitis C / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D009842:Oligopeptides / Q000008:administration & dosage / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011392:Proline / Q000008:administration & dosage / Q000031:analogs & derivatives*; D011480:Protease Inhibitors / Q000008:administration & dosage*; D012254:Ribavirin / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D009842:Oligopeptides; D011480:Protease Inhibitors; D011092:Polyethylene Glycols; D012254:Ribavirin; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline